J Breast Cancer.  2006 Dec;9(4):337-342. 10.4048/jbc.2006.9.4.337.

Prediction of additional axillary metastasis of breast cancer with positive sentinel lymph nodes

• Jung SP
• Bae JW
• Woo SU
• Lee JB
• Son GS
• Chae YS
• Jo KR
• Goo BH

• KMID: 2286606
• DOI: http://doi.org/10.4048/jbc.2006.9.4.337

Abstract

PURPOSE: Axillary lymph node dissection in breast cancer patients with positive sentinel lymph node (SLN) is accepted as a routine procedure. In a significant proportion of women with breast cancer, the SLN is the sole site of regional metastasis. These patients would not be expected to benefit from complete lymph node dissection. The purpose of this study is to determine which factors are associated with additional positive lymph nodes in the axilla of patients who have positive sentinel lymph nodes.
METHODS
Between September 2001 and May 2005, we examined 135 cases where the patients underwent a breast conserving operation and a SLN biopsy. There were 34 patients with positive SLN. Univariate analysis was used to identify the clinicopathologic features in the SLN positive patients that can predict metastasis in the nonsentinel lymph nodes (NSLNs).
RESULTS
Fifteen patients (44.1%) had metastasis in the NSLNs. There were significant differences in the location of tumors (p=0.018), the nodal status of each patient (p=0.001) and c-erbB2 protein expression (p =0.017) in NSLN metastasis as determined by univariate analysis.
CONCLUSION
The location of the breast cancer, nodal status and c-erbB2 expression are of predictive value for NSLN involvement. We suggest that a full axillary lymph node dissection may be considered as a sparing treatment in these situations.

Keyword

Breast cancer; nonsentinel lymph node; axillary lymph node dissection

MeSH Terms

Axilla
Biopsy
Breast Neoplasms*
Breast*
Female
Humans
Lymph Node Excision
Lymph Nodes*
Neoplasm Metastasis*

Reference

1. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival- a Bayesian meta-analysis. Ann Surg Oncol. 1999. 6:109–116.

2. Ivens D, Hoe A, Podd T, Hamilton C, Taylor I, Royle G. Assessment of morbidity from complete axillary dissection. Br J Cancer. 1992. 66:136–138.

3. Tasmuth T, von Smitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer. 1996. 74:2024–2031.

4. Lin P, Allison D, Wainstock J, Miller KD, Dooley WC, Friedman N, et al. Impact of axillary node dissection on the therapy of breast cancer patients. J Clin Oncol. 1993. 11:1536–1544.

5. Veronesi U, Pagnelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003. 349:546–553.

6. Cody HS 3rd. Clinical aspects of sentinel node biopsy. Breast Cancer Res. 2001. 3:104–108.

7. Clarke D, Newcombe RG, Mansel RE. ALMANAC Trialists Group. The learning curve in sentinel node biopsy: the ALMANAC experience. Ann Surg Oncol. 2004. 11:S211–S215.

8. Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999. 230:692–696.

9. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1 breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000. 191:1–6.

10. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection . Ann Surg. 1999. 229:53–41.

11. Giuliano AE, kirgran DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphnodenectomy for breast cancer. Ann Surg. 1994. 220:391–398.

12. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node:Implications of the ACOSOG Z0011 Trial Semin. Surg Onco. 2001. 20:230–237.

13. Lyman GH, Giuliano AE, Sommerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American society of clinical oncology guideline recommendations for sentinel lymph node biopsy early stage breast cancer. J Clin Onco. 2005. 23:7703–7720.

14. Wada N, Imoto S, Yamauchi C, Hasebe T, Ochiai A. Predictors of tumor involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur J Surg Oncol. 2006. 32:29–33.

15. Goyal A, Douglas-Jones , Newcombe RG, Mansel . Predictors of non-sentinel lymph node metastasis in breast cancer patients. Euro J Cancer. 2004. 40:1731–1737.

16. Reynolds C, Mick R, Donohue JH, Grant C, Farley D, Callan LS, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999. 17:1720–1726.

17. Weiser RW, Montgomery LL, Tan LK, Susnik B, leung DYH, Borgen PI, et al. Lymphovascular invasion enhances the prediction of nonsentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001. 8:145–149.

18. Lee IK, Lee SA, Jeong J, Park BW, Jung WH, Hong SW. Predicting the status of the nonsentinel lymphnodes in early breast cancer patients with positive sentinel lymph nodes. J Korean Breast Cancer Soc. 2004. 7:268–274.

19. Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001. 136:688–692.

20. Chu KU, Turner RR, Hansen NM, Brennan MB, Giuliano AE. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol. 1999. 6:756–761.

21. Fehm T, Maul H, Gebauer S, Scharf A, Baier P, Sohn C, et al. Prediction of axillary lymph node status of breast cancer patients by tumobiological factors of the primary tumor. Strahlenther Onkol. 2005. 9:580–586.

22. Cox C, DuPont EL, Furman B, Stowell N, Clark J, Ebert M, et al. The clinical relevance of positive sentinel nodes only versus positive nonsentinel lymph nodes in breast cancer patients. Am J Surg. 2003. 186:333–336.